Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Iovance BiotherapeuticsIOVA -5.66%45 Debt-to-Equity is 0.07 as of Mar. 2026, which is 13% below its 10-year median of 0.08. GuruFocus rates IOVA with a GF Score™ of 45/100 and a GF Value™ of $19.12 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 966 Biotechnology companies, Iovance Biotherapeutics ranks better than 65.63% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Iovance Biotherapeutics's Debt-to-Equity or its related term are showing as below:
IOVA'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.08 Max: 0.2
Current: 0.07
During the past 13 years, the highest Debt-to-Equity Ratio of Iovance Biotherapeutics was 0.20. The lowest was 0.01. And the median was 0.08.
IOVA's Debt-to-Equity is ranked better than 65.63% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs IOVA: 0.07
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Iovance Biotherapeutics Debt-to-Equity Related Terms
Iovance Biotherapeutics Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IOVA vs SNDX, GLUE, TYRA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Iovance Biotherapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iovance Biotherapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Iovance Biotherapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iovance Biotherapeutics (IOVA) has a Debt-to-Equity of 0.07 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Iovance Biotherapeutics and its competitors. This is 13% below median its historical median of 0.08. Over the past decade, Iovance Biotherapeutics' Debt-to-Equity has ranged from 0.01 to 0.20. According to the industry distribution chart, Iovance Biotherapeutics ranks #332 out of 966 companies in the Biotechnology industry, placing it in the top 34.4%.
Is Iovance Biotherapeutics' Debt-to-Equity too high?
Iovance Biotherapeutics' current Debt-to-Equity of 0.07 is 13% below median its 10-year median of 0.08. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.20. The Biotechnology industry median Debt-to-Equity is 0.16. Iovance Biotherapeutics' value of 0.07 is 56.3% below this industry median. Based on the distribution chart, Iovance Biotherapeutics ranks #332 out of 966 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Iovance Biotherapeutics has a GF Score™ of 45/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Iovance Biotherapeutics' Debt-to-Equity compare to SNDX and GLUE?
According to the Biotechnology industry distribution chart, Iovance Biotherapeutics ranks #332 out of 966 companies for Debt-to-Equity. This puts Iovance Biotherapeutics in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Iovance Biotherapeutics' value of 0.07 is 56.3% below this benchmark. Historically, Iovance Biotherapeutics' own Debt-to-Equity has ranged from 0.01 to 0.20 over the past decade. While the company's 10-year median is 0.08 vs. the industry median of 0.16, Iovance Biotherapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Iovance Biotherapeutics's current Debt-to-Equity of 0.07 is 56.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Iovance Biotherapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iovance Biotherapeutics's current Debt-to-Equity is 0.07, which is 13% below median its own 10-year median of 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iovance Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Iovance Biotherapeutics (IOVA) is currently considered Significantly Undervalued. The stock's GF Value™ is $19.12, compared to a current price of $5.18 — trading 72.9% below its estimated fair value. The current Debt-to-Equity is 0.07, which is 13% below median its 10-year median of 0.08 and 56.3% below the Biotechnology industry median of 0.16. Iovance Biotherapeutics' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Iovance Biotherapeutics (IOVA), the current Debt-to-Equity is 0.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Iovance Biotherapeutics (IOVA) Overvalued in 2026?
Based on GuruFocus' analysis, Iovance Biotherapeutics stock appears to be undervalued.
The current stock price of $5.18 is trading 72.9% below its estimated GF Value™ of $19.12.
GuruFocus considers Iovance Biotherapeutics to be Significantly Undervalued.
Key valuation signals for IOVA:
Debt-to-Equity: 0.07 (13% below median its 10-year median of 0.08)
GF Value™: $19.12 vs. price of $5.18 (72.9% below fair value)
Industry Position: 56.3% below the Biotechnology median (#332 of 966)
No single metric tells the full story. See the IOVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
45GF Score
Get the complete analysis for IOVA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IOVA has been successfully added to your 
